174 related articles for article (PubMed ID: 31445021)
1. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202.
Korprasertthaworn P; Chau N; Nair PC; Rowland A; Miners JO
Biochem Pharmacol; 2019 Nov; 169():113616. PubMed ID: 31445021
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Miners JO; Chau N; Rowland A; Burns K; McKinnon RA; Mackenzie PI; Tucker GT; Knights KM; Kichenadasse G
Biochem Pharmacol; 2017 Apr; 129():85-95. PubMed ID: 28065859
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human UDP-glucuronosyltransferase enzyme by Dabrafenib: Implications for drug-drug interactions.
Yin H; Wang Z; Wang X; Lv X; Fan X; Yan M; Jia Y; Jiang L; Cao J; Liu Y
Biomed Chromatogr; 2021 Nov; 35(11):e5205. PubMed ID: 34192355
[TBL] [Abstract][Full Text] [Related]
4. Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases.
Zhang N; Liu Y; Jeong H
Sci Rep; 2015 Dec; 5():17778. PubMed ID: 26642944
[TBL] [Abstract][Full Text] [Related]
5. Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors.
den Braver-Sewradj SP; den Braver MW; Baze A; Decorde J; Fonsi M; Bachellier P; Vermeulen NPE; Commandeur JNM; Richert L; Vos JC
Eur J Pharm Sci; 2017 Nov; 109():96-110. PubMed ID: 28778465
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib Carries the Risk of Drug-Drug Interactions
Wang Z; Jiang L; Wang X; Yin H; Wang Z; Lv X; Liu Y
Curr Drug Metab; 2022; 23(11):912-919. PubMed ID: 36306450
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human UDP-glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug-drug interactions.
Wang Z; Wang X; Jia Y; Yin H; Feng Y; Jiang L; Cao J; Liu Y
Biopharm Drug Dispos; 2020 Jun; 41(6):231-238. PubMed ID: 32436276
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions.
Pattanawongsa A; Chau N; Rowland A; Miners JO
Drug Metab Dispos; 2015 Oct; 43(10):1468-76. PubMed ID: 26180128
[TBL] [Abstract][Full Text] [Related]
9. Design and optimization of the cocktail assay for rapid assessment of the activity of UGT enzymes in human and rat liver microsomes.
Chen A; Zhou X; Cheng Y; Tang S; Liu M; Wang X
Toxicol Lett; 2018 Oct; 295():379-389. PubMed ID: 30036684
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase.
Wang X; Wang Z; Fan X; Yan M; Jiang L; Xia Y; Cao J; Liu Y
Toxicol Appl Pharmacol; 2021 Aug; 424():115595. PubMed ID: 34038714
[TBL] [Abstract][Full Text] [Related]
11. Inhibition screening method of microsomal UGTs using the cocktail approach.
Gradinaru J; Romand S; Geiser L; Carrupt PA; Spaggiari D; Rudaz S
Eur J Pharm Sci; 2015 Apr; 71():35-45. PubMed ID: 25684194
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of UDP-glucuronosyltransferases (UGTs) by tetraiodothyronine (T4) and triiodothyronine (T3).
Chen DW; Du Z; Zhang CZ; Zhang WH; Cao YF; Sun HZ; Zhu ZT; Yang K; Liu YZ; Zhao ZW; Fu ZW; Gu WQ; Yu Y; Fang ZZ
Xenobiotica; 2018 Mar; 48(3):250-257. PubMed ID: 28285550
[TBL] [Abstract][Full Text] [Related]
13. In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions.
Wang Z; Wang X; Wang Z; Jia Y; Feng Y; Jiang L; Xia Y; Cao J; Liu Y
Toxicol Lett; 2021 Sep; 348():10-17. PubMed ID: 34044055
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38.
Iwase M; Fujita KI; Nishimura Y; Seba N; Masuo Y; Ishida H; Kato Y; Kiuchi Y
Cancer Chemother Pharmacol; 2019 May; 83(5):993-998. PubMed ID: 30810774
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the inhibition risk of shikonin on human and rat UDP-glucuronosyltransferases (UGT) through the cocktail approach.
Cheng Y; Tang S; Chen A; Zhang Y; Liu M; Wang X
Toxicol Lett; 2019 Sep; 312():214-221. PubMed ID: 31128210
[TBL] [Abstract][Full Text] [Related]
16. UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for puerarin metabolism in human liver microsomes.
Luo CF; Cai B; Hou N; Yuan M; Liu SM; Ji H; Xiong LG; Xiong W; Luo JD; Chen MS
Arch Toxicol; 2012 Nov; 86(11):1681-90. PubMed ID: 22648071
[TBL] [Abstract][Full Text] [Related]
17. In vitro effects of opicapone on activity of human UDP-glucuronosyltransferases isoforms.
Wang Z; Wang Z; Wang X; Lv X; Yin H; Fan X; Yan M; Jia Y; Jiang L; Xia Y; Li W; Liu Y
Toxicol Lett; 2022 Aug; 367():3-8. PubMed ID: 35810997
[TBL] [Abstract][Full Text] [Related]
18. Inhibition potential of UDP-glucuronosyltransferases (Ugts) 1A isoforms by the analogue of resveratrol, bakuchiol.
Dong DG; Zhang Y; Zhang SL; Lv J; Guo EM; Fang ZZ; Cao YF
Pharmazie; 2014 Jan; 69(1):60-3. PubMed ID: 24601226
[TBL] [Abstract][Full Text] [Related]
19. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
[TBL] [Abstract][Full Text] [Related]
20. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors.
Walsky RL; Bauman JN; Bourcier K; Giddens G; Lapham K; Negahban A; Ryder TF; Obach RS; Hyland R; Goosen TC
Drug Metab Dispos; 2012 May; 40(5):1051-65. PubMed ID: 22357286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
